Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Clin Cases. Jun 26, 2022; 10(18): 6069-6081
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6069

Table 4 Possible treatment-related adverse events

	All-grade TRAE		Grade 3-4 TRAE
	Icotinib (n = 22)	Chemotherapy + icotinib (n = 34)	Icotinib (n = 22)	Chemotherapy + icotinib (n = 34)
Rash	9 (40.9)	19 (55.9)	0 (0.0)	0 (0.0)
Gastrointestinal system disorders	0 (0.0)	28 (82.4)	0 (0.0)	2 (5.9)
Alanine transaminase elevation	6 (27.3)	14 (41.2)	0 (0.0)	0 (0.0)
Aspartate aminotransferase elevation	3 (13.6)	10 (29.4)	0 (0.0)	0 (0.0)
Leukopenia	0 (0.0)	22 (64.7)	0 (0.0)	3 (8.8)
Thrombocytopenia	0 (0.0)	4 (11.8)	0 (0.0)	0 (0.0)

TRAE: Treatment-related adverse event.

Citation: Sun SJ, Han JD, Liu W, Wu ZY, Zhao X, Yan X, Jiao SC, Fang J. Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. World J Clin Cases 2022; 10(18): 6069-6081
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6069.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6069

Sun SJ, Han JD, Liu W, Wu ZY, Zhao X, Yan X, Jiao SC, Fang J. Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. World J Clin Cases 2022; 10(18): 6069-6081 [PMID: 35949840 DOI: 10.12998/wjcc.v10.i18.6069]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.